234 related articles for article (PubMed ID: 35617463)
1. Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score-matched analysis.
Nero C; Pasciuto T; Cappuccio S; Corrado G; Pelligra S; Zannoni GF; Santoro A; Piermattei A; Minucci A; Lorusso D; Fanfani F; Scambia G
Cancer; 2022 Aug; 128(15):2898-2907. PubMed ID: 35617463
[TBL] [Abstract][Full Text] [Related]
2. Endometrial cancer risk factors, treatment, and survival outcomes as per the European Society for Medical Oncology (ESMO) - European Society of Gynaecological Oncology (ESGO) - European Society for Radiotherapy and Oncology (ESTRO) risk groups and International Federation of Gynecology and Obstetrics (FIGO) staging: An experience from developing world.
Gupta N; Pandey A; Dimri K; Sehgal A; Bhagat R; Suraj ; Gill G
J Cancer Res Ther; 2023; 19(3):701-707. PubMed ID: 37470597
[TBL] [Abstract][Full Text] [Related]
3. Abnormal preoperative haematological parameters in Endometrial cancer; reflecting tumour aggressiveness or reduced response to radiotherapy?
Vrede SW; Donkers H; Reijnen C; Smits A; Visser NCM; Geomini PM; Ngo H; van Hamont D; Pijlman BM; Vos MC; Snijders MPLM; Kruitwagen R; Bekkers RLM; Galaal K; Pijnenborg JMA
J Obstet Gynaecol; 2024 Dec; 44(1):2294332. PubMed ID: 38186008
[TBL] [Abstract][Full Text] [Related]
4. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.
Concin N; Creutzberg CL; Vergote I; Cibula D; Mirza MR; Marnitz S; Ledermann JA; Bosse T; Chargari C; Fagotti A; Fotopoulou C; González-Martín A; Lax SF; Lorusso D; Marth C; Morice P; Nout RA; O'Donnell DE; Querleu D; Raspollini MR; Sehouli J; Sturdza AE; Taylor A; Westermann AM; Wimberger P; Colombo N; Planchamp F; Matias-Guiu X
Virchows Arch; 2021 Feb; 478(2):153-190. PubMed ID: 33604759
[TBL] [Abstract][Full Text] [Related]
5. Identification of
Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
[TBL] [Abstract][Full Text] [Related]
6. Integrated clinicopathologic and molecular analysis of endometrial carcinoma: Prognostic impact of the new ESGO-ESTRO-ESP endometrial cancer risk classification and proposal of histopathologic algorithm for its implementation in clinical practice.
de Biase D; Maloberti T; Corradini AG; Rosini F; Grillini M; Ruscelli M; Coluccelli S; Altimari A; Gruppioni E; Sanza V; Turchetti D; Galuppi A; Ferioli M; Giunchi S; Dondi G; Tesei M; Ravegnini G; Abbati F; Rubino D; Zamagni C; De Iaco P; Santini D; Ceccarelli C; Perrone AM; Tallini G; De Leo A
Front Med (Lausanne); 2023; 10():1146499. PubMed ID: 37064027
[TBL] [Abstract][Full Text] [Related]
7. Vaginal brachytherapy management of stage I and II endometrial cancer.
van den Heerik ASVM; Horeweg N; Creutzberg CL; Nout RA
Int J Gynecol Cancer; 2022 Mar; 32(3):304-310. PubMed ID: 35256416
[TBL] [Abstract][Full Text] [Related]
8. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
Concin N; Matias-Guiu X; Vergote I; Cibula D; Mirza MR; Marnitz S; Ledermann J; Bosse T; Chargari C; Fagotti A; Fotopoulou C; Gonzalez Martin A; Lax S; Lorusso D; Marth C; Morice P; Nout RA; O'Donnell D; Querleu D; Raspollini MR; Sehouli J; Sturdza A; Taylor A; Westermann A; Wimberger P; Colombo N; Planchamp F; Creutzberg CL
Int J Gynecol Cancer; 2021 Jan; 31(1):12-39. PubMed ID: 33397713
[TBL] [Abstract][Full Text] [Related]
9. Assessing the New 2020 ESGO/ESTRO/ESP Endometrial Cancer Risk Molecular Categorization System for Predicting Survival and Recurrence.
Ouh YT; Oh Y; Joo J; Woo JH; Han HJ; Cho HW; Lee JK; Chun Y; Lim MN; Hong JH
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473326
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of the new ESGO-ESTRO-ESP endometrial cancer risk classification on survival and recurrence in the Danish population.
Ortoft G; Høgdall C; Hansen ES; Dueholm M
Int J Gynecol Cancer; 2021 Aug; 31(8):1116-1124. PubMed ID: 34112735
[TBL] [Abstract][Full Text] [Related]
11. Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification.
Perrone E; Capasso I; De Felice F; Giannarelli D; Dinoi G; Petrecca A; Palmieri L; Foresta A; Nero C; Arciuolo D; Lorusso D; Zannoni GF; Scambia G; Fanfani F
Eur J Cancer; 2023 Jun; 186():98-112. PubMed ID: 37062213
[TBL] [Abstract][Full Text] [Related]
12. Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.
Imboden S; Nastic D; Ghaderi M; Rydberg F; Siegenthaler F; Mueller MD; Rau TT; Epstein E; Carlson JW
Gynecol Oncol; 2021 Aug; 162(2):394-400. PubMed ID: 34127276
[TBL] [Abstract][Full Text] [Related]
13. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
Concin N; Matias-Guiu X; Vergote I; Cibula D; Mirza MR; Marnitz S; Ledermann J; Bosse T; Chargari C; Fagotti A; Fotopoulou C; Martin AG; Lax S; Lorusso D; Marth C; Morice P; Nout RA; O'Donnell D; Querleu D; Raspollini MR; Sehouli J; Sturdza A; Taylor A; Westermann A; Wimberger P; Colombo N; Planchamp F; Creutzberg CL
Radiother Oncol; 2021 Jan; 154():327-353. PubMed ID: 33712263
[TBL] [Abstract][Full Text] [Related]
14. Concordance between preoperative ESMO-ESGO-ESTRO risk classification and final histology in early-stage endometrial cancer.
Daix M; Angeles MA; Migliorelli F; Kakkos A; Martinez Gomez C; Delbecque K; Mery E; Tock S; Gabiache E; Decuypere M; Goffin F; Martinez A; Ferron G; Kridelka F
J Gynecol Oncol; 2021 Jul; 32(4):e48. PubMed ID: 33908709
[TBL] [Abstract][Full Text] [Related]
15. Machine learning endometrial cancer risk prediction model: integrating guidelines of European Society for Medical Oncology with the tumor immune framework.
Bruno V; Betti M; D'Ambrosio L; Massacci A; Chiofalo B; Pietropolli A; Piaggio G; Ciliberto G; Nisticò P; Pallocca M; Buda A; Vizza E
Int J Gynecol Cancer; 2023 Nov; 33(11):1708-1714. PubMed ID: 37875322
[TBL] [Abstract][Full Text] [Related]
16. A novel algorithm to implement the molecular classification according to the new ESGO/ESTRO/ESP 2020 guidelines for endometrial cancer.
Betella I; Fumagalli C; Rafaniello Raviele P; Schivardi G; De Vitis LA; Achilarre MT; Aloisi A; Garbi A; Maruccio M; Zanagnolo V; Aletti G; Guerini-Rocco E; Mariani A; Maggioni A; Barberis M; Colombo N; Multinu F
Int J Gynecol Cancer; 2022 Jun; ():. PubMed ID: 35732351
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
Vrede SW; van Weelden WJ; Visser NCM; Bulten J; van der Putten LJM; van de Vijver K; Santacana M; Colas E; Gil-Moreno A; Moiola CP; Mancebo G; Krakstad C; Trovik J; Haldorsen IS; Huvila J; Koskas M; Weinberger V; Bednarikova M; Hausnerova J; van der Wurff AA; Matias-Guiu X; Amant F; ; Snijders MPLM; Küsters-Vandevelde HVN; Reijnen C; Pijnenborg JMA
Gynecol Oncol; 2021 Jun; 161(3):787-794. PubMed ID: 33858677
[TBL] [Abstract][Full Text] [Related]
18. Recurrence rates and patterns of recurrence in stage IA p53abn endometrial cancer with and without myometrial invasion.
Jamieson A; Grube M; Leung S; Chiu D; Lum A; Kwon JS; Talhouk A; Gilks B; Kommoss S; McAlpine JN
Int J Gynecol Cancer; 2024 Apr; 34(4):544-549. PubMed ID: 38388178
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Recurrence, Long-term Survival and Toxicity Analysis of Endometrial Adenocarcinoma Patients Reclassified Under the Recent ESMO-ESGO-ESTRO Stratification: Seven-Year Results From a Single Institution.
Kumar UP; Yathiraj PH; Sharan KT; Kamath A; Singh A; Reddy SA; Alurkar P; Fernandes DJ; Mamidipudi VS
Int J Gynecol Cancer; 2018 Jun; 28(5):854-860. PubMed ID: 29683879
[TBL] [Abstract][Full Text] [Related]
20. An easy, fast, and accurate way for implementing the standards of care for the management of patients with endometrial carcinoma into daily clinical practice: the ESGO mobile app.
Gaillard T; Schwameis R; Laas-Faron E; Eisenberg-Nissim T; Matias-Guiu X; Creutzberg CL; Ledermann J; Planchamp F; Concin N
Int J Gynecol Cancer; 2023 Aug; 33(8):1181-1184. PubMed ID: 37460218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
